Abstract:Diabetic kidney disease (DKD) is a severe microvascular complication of diabetes, one key feature of which includes renal fibrosis. As apelin is an adipokine closely related to diabetes, the present study aimed to evaluate apelin-13 expression levels and the relationship between apelin-13 and disease indicators in patients with diabetic kidney disease (DKD). The present case-control study enrolled 70 patients with diabetes, including 31 with diabetic kidney disease (DKD group), 39 without DKD (non-DKD group) and 30 healthy controls. The levels of serum apelin-13 and TGF-β1, the key driver of renal fibrosis, were determined by ELISA. Additionally, age, mean disease duration, weight, blood pressure, fasting blood glucose, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein, cholesterol, urea nitrogen, blood creatinine and 24-hour urinary total protein (24-h UTP) were recorded. The results demonstrated that apelin-13 and TGF-β1 expression levels, age, blood pressure, fasting blood glucose, cholesterol and blood urea nitrogen levels were significantly higher in patients with diabetes compared with the healthy controls (P<0.05). Moreover, apelin-13 and TGF-β1 expression levels, mean disease duration, systolic pressure, blood creatinine, blood urea nitrogen and 24-h UTP were significantly higher in the DKD group compared with the non-DKD group (P<0.05). The estimated glomerular filtration rate (eGFR) was significantly reduced in the DKD group compared with the non-DKD group (P<0.05). Correlation analysis demonstrated a negative correlation between apelin-13 and eGFR expression and a positive correlation between apelin-13 expression and 24-h UTP in both the DKD and non-DKD groups (P<0.05). A negative correlation was also demonstrated between apelin-13 and TGF-β1 expression levels in the DKD group and non-DKD groups (both P<0.05). In conclusion, apelin-13 and TGF-β1 expression levels were significantly higher in the DKD group compared with those in the non-DKD group. Additionally, apelin-13 expression was negatively correlated with TGF-β1 expression in the DKD and non-DKD groups. Therefore, apelin-13 could potentially be used in the future as an indicator of renal fibrosis or destruction in patients with DKD. The present trial was retrospectively registered in the Chinese Clinical Trial Registry (trial registration no. ChiCTR2200060945) on 14.06.2022.

The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis Through Suppression of TGFβ-Induced Endothelial-to-Mesenchymal Transition.

Apelin-13 Promotes Late Endothelial Progenitor Cells Differentiation by Regulating Krüppel-like Factor 4.

Apelin Attenuates TGF-β1-induced Epithelial to Mesenchymal Transition Via Activation of PKC-ε in Human Renal Tubular Epithelial Cells.

The Regulatory Peptide Apelin: A Novel Inhibitor of Renal Interstitial Fibrosis

Endothelial FGFR1 (fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice

Apelin/APJ System: A Novel Potential Therapy Target for Kidney Disease

Apelin Inhibits Angiotensin II-Induced Atrial Fibrosis and Atrial Fibrillation Via TGF-β1/Smad2/α-SMA Pathway

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

The apelin-APJ axis: A novel potential therapeutic target for organ fibrosis.

Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse.

GW24-e3625 Effects of apelin on the phosphodiesterase 1 expression and oxidative stress levels in mouse kidney fibroblast cells

Apelin Protects Against Acute Renal Injury by Inhibiting TGF-β1.

RUNX3-activated apelin signaling inhibits cell proliferation and fibrosis in diabetic nephropathy by regulation of the SIRT1/FOXO pathway

Expression of apelin‐13 and its negative correlation with TGF‐β1 in patients with diabetic kidney disease

Effects of Apelin on the Fibrosis of Retinal Tissues and Müller Cells in Diabetes Retinopathy Through the JAK2/STAT3 Signalling Pathway.

Apigenin inhibits epithelial mesenchymal transition in renal tubular epithelial cells through PI3K/AKT and NF-κB pathways for treating renal fibrosis

C3a and C5a Receptor Antagonists Ameliorate Endothelial-Myofibroblast Transition Via the Wnt/β-catenin Signaling Pathway in Diabetic Kidney Disease.

Ascending Aortic Adventitial Remodeling and Fibrosis Are Ameliorated with Apelin-13 in Rats after TAC Via Suppression of the Mirna-122 and LGR4-β-catenin Signaling.

Bioactive Peptide Apelin Rescues Acute Kidney Injury by Protecting the Function of Renal Tubular Mitochondria

Advances in understanding the role of adiponectin in renal fibrosis

Apelin ameliorated acute heart failure via inhibiting endoplasmic reticulum stress in rabbits